Friday, Oct. 20, from 1:30 to 7 p.m., at Pembroke Academy, 209 Academy Road. Friday, Oct. 20, from 10 a.m. to 4 p.m., at Catholic Medical Center, 100 McGregor St.. Monday, Oct. 30, from 10 a.m. to 4 p.m., at Elliot Hospital, One Elliot Way.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will be one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. Food and Drug Administration announced today is the first approved CAR-T cell therapy for adult patients with certain types of large B-cell lym
It has been asked throughout history: Haven't Native American tribes suffered enough? In September, the drug maker Allergan gave six patents for the drug Restasis to the upstate New York- based Saint Regis Mohawk Tribe, and paid the tribe $13.5 million to accept the patents and grant an exclusive license, also promising $15 million annually until t
Endo Pharmaceuticals, Malvern, Pennsylvania, has been assigned a patent developed by Harry Ahdieh, Lincoln University, Pennsylvania, for a "method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment." The patent application was filed on July 21, 2014. Written by Kusum
Diagnosed with Duchenne muscular dystrophy when he was 2, Tommy Parzymieso, a 9- year-old Eggert Elementary student, has been battling the disease most of his life as his family seeks a drug to aid his fight against the progressive muscle-wasting condition. The meeting was held after PTC Therapeutics, the company that developed the drug, filed on t
The U.S. Food and Drug Administration approved a new form of cell-based gene therapy for adults with certain types of large B-cell lymphoma, marking only the second time a gene therapy has been approved for the disease. The FDA said diffuse large B-cell lymphoma is the most common type of non-Hodgkin's Lymphona in adults and there are approximately
Oct. 19 The Foundation Fighting Blindness announced Wednesday that it has named Benjamin Yerxa as its new CEO, effective immediately. He previously served as president and co-founder of Envisia Therapeutics, a privately held biotechnology company that works on ocular therapies. He also served in posts at several ophthalmology-based R&D organizati
The Federal Trade Commission issued the following news release:. The workshop, titled "Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics," will take place on November 8, 2017 at the FTC's Constitution Center Auditorium, 400 7th St., SW, Washington, DC. Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and
I'm concerned that my 80- year-old mother is taking too many medications. According to the Journal of the American Medical Association, around 40 percent of seniors, age 65 and older, take five or more medications. You should also note that October 21, is "National Check Your Meds Day.
According to the American Cancer Society, nearly 1.7 million new cases of cancer are expected in the U.S. this year. Friday, Oct. 20, from 10 a.m. to 4 p.m., at Catholic Medical Center, 100 McGregor St.. Monday, Oct. 30, from 10 a.m. to 4 p.m., at Elliot Hospital, One Elliot Way.
Nanotherapeutics Announces Name Change to Ology Bioservices, Reflecting the Company's Ongoing Transformation into One of the Top Contract Development and Manufacturing Organizations of Vaccines and Biologics. By a News Reporter-Staff News Editor at Gene Therapy Weekly Nanotherapeutics, Inc. announced that the Company has changed its name to Ology
By a News Reporter-Staff News Editor at Gene Therapy Weekly A patent by the inventors Mannino, Raphael; Lu, Ruying, filed on January 29, 2015, was published online on October 3, 2017, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. Patent number 9775907 is assigned to MATINAS BIOPHARMA NANOTECHNOLOGIES
Note: Media reports indicate that President Donald Trump is likely to nominate Alex Azar, who served for five years as president of Lilly USA, LLC, the largest affiliate of global biopharmaceutical leader Eli Lilly and Company, to be the next U.S. Secretary of Health and Human Services. "Just days after denouncing" out-of-control "drug prices, Pre
News: The Company presented encouraging interim data from its phase II study evaluating Poziotinib in EGFR Exon 20 mutant non-small cell lung cancer at the 18th IASLC World Conference on Lung Cancer in Japan. The transaction provides Endocyte with 177 Lu-PSMA-617, a phase III-ready prostate cancer drug. Endocyte plans to seek regulatory approval to
By a News Reporter-Staff News Editor at Gene Therapy Weekly Nearly 800 executives from the life science industry attended BioPharm America? 2017 life science partnering event in Boston last week. The tenth annual event was held over two days, September 26-27, at the Sheraton Boston, in conjunction with several Biotech Week Boston events at the
Oct. 18 Two Tucson- area companies showcased new technologies to the Department of Defense recently after winning national honors for innovation. Tucson- based NuvOx Pharma, founded by University of Arizona radiology professor Dr. NuvOx already is conducting pre-clinical studies of the drug for treatment of traumatic brain injury with the Navy, u
Wellesley Pharmaceuticals, Newtown, Pennsylvania, has been assigned a patent developed by two co-inventors for the "extended-release formulation for reducing the frequency of urination and method of use thereof." The co-inventors are David A. Dill, Newtown, Pennsylvania, and Ilya A. Volfson, Newtown Square, Pennsylvania. Written by Kusum Sangma; ed
Global law firm White& Case LLP advised NeuroDerm Ltd., a clinical-stage pharmaceutical company developing drugs for central nervous system diseases, on its acquisition by Mitsubishi Tanabe Pharma Corporation for a total of US $1.1 billion at a price per share of US $39. NeuroDerm completed its IPO and listing on the Nasdaq in November 2014 at a pr
By a News Reporter-Staff News Editor at Biotech Week A patent application by the inventors Tu, Hosheng; Haffner, David Steven; Smedley, Gregory T.; Niksch, Barbara A.; Gharib, Morteza; Burns, Thomas W.; Lindstrom, Richard, filed on February 6, 2017, was made available online on October 5, 2017, according to news reporting originating from Washing
Nuclear Medicine Drug Unit Dose contract more info: Location: UNITED STATES BidDate: 9/ 25/ 2017 Tender Country: UNITED STATES Tender Type: Tenders Tendering Authority: Department of Veterans Affairs Tendering Authority Address: Address: Department of Veterans Affairs Great Lakes Acquisition Center 115 S 84th Street Suite 101 WI 53214-1476 Point Of
Projected full-year adjusted diluted EPS from continuing operations is now $2.48 to $2.50, which represents an increase at the mid-point of the guidance range. In September, Abbott received U.S. FDA approval for its FreeStyle Libre glucose monitoring system as a replacement 1 for finger stick blood glucose monitoring. This revolutionary technolo
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 18, 2017/ PRNewswire/ AbbVie, a global biopharmaceutical company, and Harpoon Therapeutics, a biotechnology company developing novel T-cell recruiting biologic therapies, announced today that they have entered an immuno-oncology research collaboration. The goal of the collaboration is to i
Release date- 17102017- NEW YORK- Actinium Pharmaceuticals Inc., a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that it will present at the BIO Investor Forum being held on October 16-17th at the Westin St. Francis Hotel in San Francisco, California.
Release date- 17102017- PRINCETON, N.J.- Agile Therapeutics Inc.,, a women's healthcare company, today announced the presentation of additional results from the Phase 3 SECURE trial of its investigational low-dose combination hormonal contraceptive patch, Twirla. Anita Nelson, MD, Professor and Chair of Obstetrics and Gynecology at the College of O
The ADSs described above are being offered by Akari pursuant to its shelf registration statement on Form F-3 previously filed with the Securities and Exchange Commission and declared effective by the SEC. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC